At the news
? NEUTRALIMPACT 4/10 8-K filed May 12, 2026 at 07:44 ET
Vistagen announced preliminary positive safety and exploratory efficacy data from the open-label extension (OLE) of its PALISADE-3 Phase 3 study of fasedienol for social anxiety disorder. The OLE data showed fasedienol was well-tolerated over up to 12 months of as-needed use, with clinically relevant improvements on anxiety scales over four months. However, the randomized, placebo-controlled portion of PALISADE-3 failed its primary endpoint in December 2025, so this open-label data does not change the drug's regulatory path and the stock's binary risk profile remains tied to the upcoming PALISADE-4 topline results.
- PALISADE-3 OLE safety data (n=341): fasedienol well-tolerated up to 12 months, 2.6% discontinuation rate due to AEs, no drug-related SAEs.
- Exploratory efficacy: LSAS mean improvement of 25.4 points at Month 4 (n=228, 56% had ≥20-point improvement); SPIN mean improvement of 12.4 points at Month 4 (n=228, 55% had ≥10-point improvement).
- The randomized, double-blind portion of PALISADE-3 failed its primary endpoint in December 2025, no treatment difference vs placebo on SUDS.
- PALISADE-4 topline data expected in Q2 2026; Phase 2 Repeat Dose Study topline expected in Q3 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access